ArticleBMC pulmonary medicine2026
Development and validation of a comprehensive immune-related gene signature for prognostic stratification in stage I lung adenocarcinoma.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increased detection of stage I lung adenocarcinoma (LUAD) through low-dose spiral CT highlights the need for better prognostic tools. This study developed an immune-related gene signature to predict outcomes and guide personalized management.
methodsImmune-related genes from the ImmPort database were analyzed using univariate Cox and LASSO regression. A multivariate Cox model and nomogram were constructed, with performance evaluated via ROC curves, decision curve analysis, and calibration curves. The model was validated in two independent datasets. Patients were stratified by risk score, followed by differential gene expression, enrichment, and immune infiltration analyses.
resultsA 29-gene signature was established and validated, showing robust AUC values and clinical utility. Enrichment analysis linked the signature to tumor progression and metastasis. High-risk patients exhibited higher tumor purity and lower immune/stromal scores, indicating an immunosuppressive microenvironment.
conclusionThis immune-related gene signature enables risk stratification and supports personalized treatment strategies for stage I LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.